At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 233 enrolled
Drug / intervention
Psilocybindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
In Brief
A Phase 2 clinical trial evaluating Psilocybin for Treatment Resistant Depression. Completed, enrolled 233 participants across 25 sites in 10 countries.
Detailed Summary
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTreatment Resistant Depression
CountriesCanada, Czechia, Denmark, Germany, Ireland, Netherlands, Portugal, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedDec 2018
Enrollment StartMar 2019
Primary CompletionJul 2021
Study CompletionSep 2021
TodayJul 2026
First PostedDec 13, 2018
Enrollment StartMar 1, 2019
Primary CompletionJul 30, 2021
Study CompletionSep 27, 2021
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 7.6 years ago
Interventions
Psilocybindrug
Dose-finding